Through the Community Research Fund Program, the Oligodendroglioma Research Fund supports promising research specifically targeted at creating new treatments for oligodendroglioma and improving patients’ lives.
Since 2013, NBTS has funded projects from top researchers focusing on oligodendroglioma. To date, this research has identified key advances in the knowledge of oligodendroglioma tumors, and how they grow and develop. These new insights will help pave the way to more effective treatments for this tumor type.
The Oligo Advisory Council performs a rigorous review of each grant application to select the projects that best meet the needs of the current oligo research landscape. Recipients receive a restricted grant of $300,000 over two years to fund their projects. Oligo Research Fund grant recipients are:
David Louis, MD, Harvard Medical School, Massachusetts General Hospital
Mapping the epigenomic landscape of oligodendroglioma to elucidate tumor growth and chemosensitivity
Anders Persson, PhD, University of California, San Francisco
IDH1R132H-induced transformation of oligodendrocyte progenitor cells into oligodendroglioma
Robert Jenkins, MD, PhD and Daniel Lachance, MD, Mayo Clinic
The Functional Biology of Germline Predisposition to Oligodendroglioma
Both researchers will lead projects that seek to determine what causes Oligo tumors to develop and subsequently grow through next-generation sequencing (Louis), and tumor modeling (Persson), so that future investigations can better understand what biomarkers to target with potential therapies.